Skip to content

Platelet Transfusions in Critically Ill Patient

Platelet Transfusion Efficacy in Critically Ill Patients

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03325140
Acronym
RE-CCIP
Enrollment
300
Registered
2017-10-30
Start date
2018-05-30
Completion date
2019-12-15
Last updated
2019-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Critical Illness, Platelet Transfusion

Brief summary

Between 10 and 15% of critically ill patients require platelet transfusion within their intensive care unit (ICU). Platelets (PLT) are given to prevent bleeding in thrombocytopenic patients or to treat bleeding as part of massive transfusion or in bleeding thrombocytopenic patients. International and local guidelines (American Association of Blood Banks-AABB) are mainly based on experts' opinion. The efficacy of PLT transfusion in the ICU setting remains poorly studied and unknown and the administration of PLT may be associated with adverse effects including an increased risk of hospital acquired infection. Finally, the short PLT shelve-life may be responsible for inventory issues. Altogether, this makes very important to improve the evidence that support PLT transfusion in ICU patients. This is a multicentre prospective observational study that aims to first determine PLT transfusion efficacy and to identify the parameters associated with transfusion efficacy and to analyse the compliance with international (and local) guidelines of PLT transfusion in ICU patients.

Interventions

None listed

Sponsors

University Hospital, Brest
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients admitted to intensive care and receiving at least one platelet transfusion in intensive care unit

Exclusion criteria

* Age less than 18

Design outcomes

Primary

MeasureTime frameDescription
platelet transfusion efficacybetween 18 hours and 28 days after transfusioncorrected count platelet increment

Countries

France

Contacts

Primary ContactAUBRON Cécile
cecile.aubron@chu-brest.fr+33 2 98 34 78 59

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026